Orthofix lowers 2026 revenue outlook to $825M–$830M on soft US spine business
The device maker now expects adjusted EBITDA of $86M–$88M for the year, as growth in limb reconstruction and therapeutic solutions fails to offset a 4.3% fall in US spine sales.
Orthofix Medical has reduced its full-year 2026 financial targets, pointing to weakness in its US spine business. According to the company's November 2026 investor presentation, it now expects net sales of $825M–$830M and adjusted EBITDA of $86M–$88M. The figures are stated as of 9 November 2026.
Third-quarter net sales were $207.9M, up 2% on a pro forma, constant-currency basis against the same period a year earlier. Adjusted EBITDA for the quarter was $26.0M.
The mix beneath that headline growth is uneven. Limb reconstruction and therapeutic solutions both grew, but US spine sales fell 4.3%. The lowered outlook comes after that shortfall.
Orthofix also said it is working to improve free cash flow. The material available for this report gives no detail on the measures involved or any targets. The full presentation text was not available, and the prior outlook figures are not covered here, so the size of the cut cannot be calculated from this information.
Orthofix is a medical device company rather than a drug developer. The available information includes no regulatory, quality or safety developments.
Why it matters
- Orthofix's softness is concentrated in US spine; limb reconstruction and therapeutic solutions are still growing.
- The new full-year range is $825M–$830M in net sales and $86M–$88M in adjusted EBITDA, a reference point for suppliers and partners revisiting volume assumptions.
- Free cash flow is a stated priority, but no specifics were available, so any read on cost or investment plans would be premature.
Company's press release (SEC filing): Orthofix Medical Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
